Chronic Lymphocytic Leukemia Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Chronic Lymphocytic Leukemia stocks.

Chronic Lymphocytic Leukemia Stocks Recent News

Date Stock Title
Nov 1 TEVA Teva long-acting olanzapine shows improvements in schizophrenia patients
Nov 1 TEVA Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition
Nov 1 TEVA Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanzapine) a Subcutaneous Long-Acting Injectable as well ...
Nov 1 TEVA Countdown to Teva Pharmaceutical Industries (TEVA) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
Nov 1 BIIB Biogen partner Eisai completes FDA submissions for injectable Alzheimer’s therapy
Nov 1 LGND Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston
Nov 1 TEVA EC fines Teva $502m over multiple sclerosis treatment Copaxone practices
Nov 1 BIIB Biogen Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Oct 31 BIIB Biogen Q3 Earnings Review: Why I Remain Optimistic Despite Difficult Quarter
Oct 31 TEVA Teva fined $500M by EU for disparaging rival MS drug (update)
Oct 31 BIIB Biogen down as Morgan Stanley cuts rating on sluggish Alzheimer’s drug launch
Oct 31 BIIB Biogen slips as Morgan Stanley downgrades on Leqembi launch
Oct 31 TEVA EU Commission fines Teva $500 million for trying to stop rival's multiple sclerosis drug
Oct 31 TEVA Teva Fined Around $500 Million by EU Over MS Drug Competition Concerns
Oct 31 TEVA Teva Statement on European Commission Decision; Company to Appeal
Oct 31 BIIB Biogen Inc (BIIB) Q3 2024 Earnings Call Highlights: Navigating Revenue Declines and Strategic ...
Oct 30 BIIB Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference
Oct 30 BIIB Biogen Beats on Q3 Earnings & Sales, Raises '24 EPS View
Oct 30 BIIB Biogen and Neomorph enter molecular glue degrader deal
Oct 30 BIIB Biogen (BIIB) Q3 2024 Earnings Call Transcript
Chronic Lymphocytic Leukemia

Chronic lymphocytic leukemia (CLL) is a type of cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell). Early on there are typically no symptoms. Later non-painful lymph nodes swelling, feeling tired, fever, or weight loss for no clear reason may occur. Enlargement of the spleen and anemia may also occur. It typically worsens gradually.Risk factors include having a family history of the disease. Exposure to Agent Orange and certain insecticides might also be a risk. CLL results in the buildup of B cell lymphocytes in the bone marrow, lymph nodes, and blood. These cells do not function well and crowd out healthy blood cells. CLL is divided into two main types: those with a mutated IGHV gene and those without. Diagnosis is typically based on blood tests finding high numbers of mature lymphocytes and smudge cells.Management of early disease is generally with watchful waiting. Infections should more readily be treated with antibiotics. In those with significant symptoms, chemotherapy or immunotherapy may be used. The medications fludarabine, cyclophosphamide, and rituximab are typically the initial treatment in those who are otherwise healthy.CLL affected about 904,000 people globally in 2015 and resulted in 60,700 deaths. The disease most commonly occurs in people over the age of 50. Males are affected more often than females. It is much less common in people from Asia. Five-year survival following diagnosis is approximately 83% in the United States. It represents less than 1% of deaths from cancer.

Browse All Tags